首页> 外文期刊>BMC Public Health >Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?
【24h】

Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?

机译:亚临床动脉粥样硬化,心血管健康和疾病风险:在一级预防人群中是否存在心血管健康指数?

获取原文
           

摘要

Current primary prevention guidelines for cardiovascular disease (CVD) prioritize risk identification, risk stratification using clinical and risk scores, and risk reduction with lifestyle interventions and pharmacotherapy. Subclinical atherosclerosis is an early indicator of atherosclerotic burden and its timely recognition can slow or prevent progression to CVD. Thus, individuals with subclinical atherosclerosis are a priority for primary prevention. This study takes a practical approach to answering a challenge commonly faced by primary care practitioners: in patients with no known CVD, how can individuals likely to have subclinical atherosclerosis be easily identified using existing clinical data and/or information provided by the patient? Using NHANES (1999–2004), 6091 men and women aged ≥40?years without any CVD comprised the primary prevention population for this study. Subclinical atherosclerosis was determined via ankle-brachial index (ABI) using established cutoffs (subclinical atherosclerosis defined as ABI (0.91–0.99); normal defined as ABI (1.00–1.30)). Three common scores were calculated: the Framingham Risk Score (FRS), the Metabolic Syndrome (MetS), and the Cardiovascular Health Index (CVHI). Logistic regression analysis assessed the association between these scores and subclinical atherosclerosis. The sensitively and specificity of these scores in identifying subclinical atherosclerosis was determined. In eligible participants, 3.8% had subclinical atherosclerosis. Optimum and average CVHI was associated with decreased odds for subclinical atherosclerosis. High, but not intermediate-risk, FRS was associated with increased odds for subclinical atherosclerosis. MetS was not associated with subclinical atherosclerosis. Of the 3 scores, CVHI was the most sensitive in identifying subclinical atherosclerosis and had the lowest number of missed cases. The FRS was the most specific but least sensitive of the 3 scores, and had almost 10-fold more missed cases vs. the CVHI. The MetS had “middle” sensitivity and specificity, and 10-fold more missed cases vs. the CVHI. Results from this study suggest that routine administration of the CVHI in a primary prevention population would yield the benefits of identifying patients with existing subclinical CVD not identified through traditional CVD risk factors or scores, and bring physical activity and nutrition to the forefront of provider-patient discussions about lifestyle factors critical to maintaining and prolonging cardiovascular health.
机译:当前针对心血管疾病(CVD)的初级预防指南优先考虑风险识别,使用临床和风险评分进行风险分层以及通过生活方式干预和药物治疗降低风险。亚临床动脉粥样硬化是动脉粥样硬化负担的早期指标,其及时识别可减慢或预防进展为CVD。因此,患有亚临床动脉粥样硬化的个体是一级预防的重点。这项研究采用了一种实用的方法来应对初级保健从业者通常面临的挑战:在没有已知CVD的患者中,如何使用现有的临床数据和/或患者提供的信息轻松识别可能患有亚临床动脉粥样硬化的个体?使用NHANES(1999-2004年),本研究的主要预防人群为6091岁年龄≥40岁且无任何CVD的男女。亚临床动脉粥样硬化是通过踝臂指数(ABI)使用既定的临界值确定的(亚临床动脉粥样硬化定义为ABI(0.91-0.99);正常定义为ABI(1.00-1.30))。计算了三个常见的分数:弗雷明汉风险评分(FRS),代谢综合症(MetS)和心血管健康指数(CVHI)。 Logistic回归分析评估了这些评分与亚临床动脉粥样硬化之间的关联。确定了这些评分在鉴定亚临床动脉粥样硬化中的敏感性和特异性。在符合条件的参与者中,有3.8%患有亚临床动脉粥样硬化。最佳和平均CVHI与亚临床动脉粥样硬化的几率降低相关。高风险(但不是中等风险)的FRS与亚临床动脉粥样硬化的可能性增加有关。 MetS与亚临床动脉粥样硬化无关。在这3个评分中,CVHI在识别亚临床动脉粥样硬化中最敏感,漏诊病例最少。 FRS是3个评分中最具体但最不敏感的,与CVHI相比,漏诊病例多了近10倍。 MetS具有“中等”的敏感性和特异性,与CVHI相比,漏诊病例多了10倍。这项研究的结果表明,在一级预防人群中常规使用CVHI将产生识别通过传统CVD危险因素或得分无法识别的现有亚临床CVD患者的优势,并将体育锻炼和营养置于提供者患者的最前沿关于维持和延长心血管健康至关重要的生活方式因素的讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号